0001104659-23-009465.txt : 20230201
0001104659-23-009465.hdr.sgml : 20230201
20230201214105
ACCESSION NUMBER: 0001104659-23-009465
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230201
DATE AS OF CHANGE: 20230201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAGNONI PABLO J
CENTRAL INDEX KEY: 0001205703
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38586
FILM NUMBER: 23578618
MAIL ADDRESS:
STREET 1: ONYX PHARMACEUTICALS, INC.
STREET 2: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rubius Therapeutics, Inc.
CENTRAL INDEX KEY: 0001709401
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042688109
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-679-9600
MAIL ADDRESS:
STREET 1: 399 BINNEY STREET, SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
tm235103-4_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-02-01
0
0001709401
Rubius Therapeutics, Inc.
RUBY
0001205703
CAGNONI PABLO J
C/O VERDOLINO & LOWEY, P.C.
124 WASHINGTON ST.
FOXBOROUGH
MA
02035
1
0
0
0
Common Stock
2023-02-01
4
S
0
8448
0.25
D
66082
D
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
/s/ Jennifer Kamocsay, attorney-in-fact
2023-02-01